UNSPSC 51385808: Piroxicam olamine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13N3O4S.C2H7NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4O2MP4507, chemically known as 2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-n-2-pyridinyl-,1,1-dioxide, compd with 2-aminoethanol (1:1) but more generally known as piroxicam olamine, which bears US NIH Compound Identifier 5745802.

UNSPSC 51385808 Piroxicam olamine is a Commodity code that nominally describes a nonsteroidal anti-inflammatory drug; however, recent state and local procurement activity under this code does not reflect direct purchasing of piroxicam olamine itself. Instead, the code appears to tag broader pharmaceutical and medical-supply procurement initiatives, including naloxone acquisition, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and market-intelligence gathering for direct-to-manufacturer pharmacy programs. State and local buyers using this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work under the code's recent activity reflects public-health and institutional-pharmacy support — emergency naloxone procurement for community health initiatives, statewide generic pharmaceutical contracting to serve multiple state and local facilities, and strategic exploration of direct-contracting pharmacy models.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the contract runs two years with a one-year renewal option and includes E-Verify and workers' compensation requirements. The Texas HHS Commission posted a Request for Information (RFI HHS0017013, due April 3, 2026) to solicit vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed as an exploratory phase before formal RFP issuance. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon, with pricing weighted at 75 percent of evaluation and contract terms of two years for new vendors effective July 1, 2026. The mismatch between the code's nominal scope (piroxicam olamine) and the actual opportunities being solicited (naloxone, generic pharmaceuticals, pharmacy-benefit programs) suggests the code is being used as a catch-all pharmaceutical tag by some issuing bodies rather than for piroxicam-specific procurement.